Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial

Pierre Renaudin, Karine Baumstarck, Aurélie Daumas, Marie-Anne Esteve, Stéphane Gayet, Pascal Auquier, Michel Tsimaratos, Patrick Villani, Stéphane Honore, Pierre Renaudin, Karine Baumstarck, Aurélie Daumas, Marie-Anne Esteve, Stéphane Gayet, Pascal Auquier, Michel Tsimaratos, Patrick Villani, Stéphane Honore

Abstract

Background: Early hospital readmission of patients after discharge is a public health problem. One major cause of hospital readmission is dysfunctions in integrated pathways between community and hospital care that can cause adverse drug events. Furthermore, the French ENEIS 2 study showed that 1.3% of hospital stays originated from serious adverse drug events in 2009. Pharmacy-led medication reviews at hospital transitions are an effective means of decreasing medication discrepancies when conducted at admission or discharge. However, it is difficult to assess the true impact of pharmacist-led medication reviews in specific high-risk populations, such as pediatric and geriatric populations. In such a context, it is important to demonstrate the effectiveness of medication reconciliation as part of a standardized medication review process-in pediatric and elderly populations-on all-cause readmissions in a large randomized controlled clinical trial. The aim of this study is to assess the impact of the pharmacist-led medication review on the rate of readmissions and/or death after hospital discharge and patient treatment satisfaction.

Methods/design: The study is a randomized controlled clinical trial. A total of 1400 hospitalized patients will be randomized in two groups: (1) the experimental group (group receiving a pharmacist-led medication review) and (2) the control group (group receiving usual care). The pharmacist-led medication review process includes medication reconciliation, treatment review and medication liaison service. The primary endpoint will be the rate of readmissions and/or death at 30 days following initial hospitalization discharge. The secondary endpoints will be the rate of hospital readmission, the rate of emergency department visits, the rate of mortality, the number of consultations and patient treatment satisfaction at 30 days following initial hospitalization discharge.

Discussion: A randomized controlled trial provides the most extensive evidence on the impact of pharmacist-led medication reviews on early hospital readmission for extreme age populations.

Trial registration: Current Controlled Trials, NCT02734017 . Registered on 4 May 2016.

Keywords: Clinical pharmacy; Geriatrics; Medication reconciliation; Medication review; Pediatrics; Pharmacists; Randomized controlled trial.

Figures

Fig. 1
Fig. 1
Template ConcReHosp Study
Fig. 2
Fig. 2
ConcReHosp study - flow of the intervention

References

    1. Zafar A, Hickner J, Pace W, Tierney W. An adverse drug event and medication error reporting system for ambulatory care (MEADERS) AMIA Annu Symp Proc. 2008;2008:839–43.
    1. Michel P, others. Enquête nationale sur les événements indésirables liés aux soins (ENEIS). Dir. Rech. Études L’évaluation Stat. DREES. 2011.
    1. Doerper S, Morice S, Piney D, Dony A, Baum T, Perrin F, et al. La conciliation des traitements médicamenteux: logigramme d’une démarche efficiente pour prévenir ou intercepter les erreurs médicamenteuses à l’admission du patient hospitalisé. Pharm Hosp Clin. 2013;48:153–60.
    1. Sullivan C, Gleason KM, Rooney D, Groszek JM, Barnard C. Medication reconciliation in the acute care setting: opportunity and challenge for nursing. J Nurs Care Qual. 2005;20:95–8. doi: 10.1097/00001786-200504000-00001.
    1. Huynh C, Wong IC, Tomlin S, Terry D, Sinclair A, Wilson K, et al. Medication discrepancies at transitions in pediatrics: a review of the literature. Pediatr Drugs. 2013;15:203–15. doi: 10.1007/s40272-013-0030-8.
    1. HAS, DGOS, DGS. Programme national pour la sécurité des paitents (PNSP) INSTRUCTION DGOS/PF2/2013/298 du 12 juillet 2013 relative au programme national pour la sécurité des patients. 2013.
    1. Assuring medication accuracy at transitions in care. World Health Organisation. Patient safety solutions. 2007. .
    1. Clyne W, Blenkinsopp A, Seal R. A Guide to Medication Review 2008. 2008;500:9.
    1. Mekonnen AB, McLachlan AJ, Brien JE. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther [Internet]. 2016 [cited 2016 Mar 10]; Available from: .
    1. Mekonnen AB, Mclachlan AJ, Jo-Anne EB. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open. 2016;6:e010003. doi: 10.1136/bmjopen-2015-010003.
    1. Renaudin P, Boyer L, Esteve M-A, Bertault-Peres P, Auquier P, Honore S. Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:1660-73.
    1. Thomas R, Huntley AL, Mann M, Huws D, Elwyn G, Paranjothy S, et al. Pharmacist-led interventions to reduce unplanned admissions for older people: a systematic review and meta-analysis of randomised controlled trials. Age Ageing. 2014;43:174–87. doi: 10.1093/ageing/aft169.
    1. Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65:303–16. doi: 10.1111/j.1365-2125.2007.03071.x.
    1. Hohl CM, Wickham ME, Sobolev B, Perry JJ, Sivilotti MLA, Garrison S, et al. The effect of early in-hospital medication review on health outcomes: a systematic review. Br J Clin Pharmacol. 2015;80:51–61. doi: 10.1111/bcp.12585.
    1. Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2014;77:102–15. doi: 10.1111/bcp.12140.
    1. Scullin C, Scott MG, Hogg A, Mcelnay JC. An innovative approach to integrated medicines management. J Eval Clin Pract. 2007;13:781–8. doi: 10.1111/j.1365-2753.2006.00753.x.
    1. Spinewine A, Swine C, Dhillon S, Lambert P, Nachega JB, Wilmotte L, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized controlled trial. J Am Geriatr Soc. 2007;55:658–65. doi: 10.1111/j.1532-5415.2007.01132.x.
    1. Zhang C, Zhang L, Huang L, Luo R, Wen J. Clinical pharmacists on medical care of pediatric inpatients: a single-center randomized controlled trial. PLoS One. 2012;7:e30856. doi: 10.1371/journal.pone.0030856.
    1. Gillespie U, Alassaad A, Henrohn D, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: A randomized controlled trial. Arch Intern Med. 2009;169:894–900. doi: 10.1001/archinternmed.2009.71.
    1. Lipton HL, Bird JA. The impact of clinical pharmacists’ consultations on geriatric patients’ compliance and medical care use: a randomized controlled trial. Gerontologist. 1994;34:307–15. doi: 10.1093/geront/34.3.307.
    1. Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)©. Value Health. 2008;11:913–26. doi: 10.1111/j.1524-4733.2008.00323.x.
    1. Delestras S, Roustit M, Bedouch P, Minoves M, Dobremez V, Mazet R, et al. Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases. PLoS One. 2013;8:e56247. doi: 10.1371/journal.pone.0056247.
    1. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32. doi: 10.1186/1745-6215-11-32.
    1. French code of public health about biomedical research and patient protection. Section R1121-3. Edict n°2006-477 from April 26th 2006 - art. 1 official Journal of the French republic April 27th 2006.
    1. Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003. .

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit